KDR and non-small cell lung carcinoma: As the antibody agianst VEGF or VEGFR, bevacizumab or ramucirumab added to chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) in advanced nonsquamous NSCLC [5–6].